John Hubbard Interview
Please write a half-page or a little longer double-spaced high level concise masters level summary of (key points including key leadership points of what he said about leadership and how to apply it) from the John Hubbard Interview
**Please utilize the following audio recording and interview transcript which will be attached**
**Synopsis**
John has more than 34 years of leadership experience in the biopharmaceutical and pharma services industries. He was the President and Chief Executive Officer of Bioclinica, a leading provider of medical imaging, clinical technologies, and development services. Over three years, Bioclinica doubled in size, completed four acquisitions, and expanded its customer base to more than 400 corporations, including the top 100 biopharmaceutical companies and top ten CROs. Bioclinica was sold to a global Private Equity firm and John retired as CEO in January 2018.
Prior to Bioclinica, John was Senior Vice President and Worldwide Head of Development Operations at Pfizer, where he directed and led global clinical operations and development. He was a member of the Portfolio Strategy and Investment Committee, Co-Chair of the Clinical and Medical Excellence Innovation Board, Co-Chair of the Early Development Committee, and also served on the executive task force that redesigned Pfizer’s R&D organization. John was a founding member of the Board of Directors of TransCelerate Biopharma, Inc., a leading biopharma industry consortium, and served on the Executive, Audit, and Finance Committees.
Before joining Pfizer, he was Group President of ICON plc’s Global Clinical Research Services Division, the company’s largest business unit generating over $750 million in revenues in 2010. During John’s tenure, ICON was named one of the country’s fastest-growing companies by FORTUNE and achieved record growth from $85 million in annual revenues in 1999 to over $900 million in revenues in 2010, becoming one of the top “5” global CROs.
John has also held executive positions at Parexel InternationalCorporation and Sanofi Pharmaceuticals (formerly Hoechst MarionRoussel Pharmaceuticals). He is currently Chairman of the SignantHealth Board and a Board Member of Advarra, two of Genstar’sportfolio companies, and also on Science 37 and Agile Therapeutics(NASDAQ: AGRX) Board of Directors. He is an ExecutiveCommittee Member Emeritus on the Clinical Trials TransformationInitiative, and former Board Member of Life Sciences PA andChairman of the Board of the Association of Clinical ResearchOrganizations (ACRO).
John received his B.S. in Psychology from the University of Santa Clara in 1978 with an emphasis in the biological basis of behavior.He went on to receive a Ph.D. in Cardiovascular Psychophysiology in 1983 from the University of Tennessee and was a National Institute of Health Postdoctoral Fellow in Cardiovascular and Autonomic Pharmacology at the University of Texas Health Sciences Center in San Antonio, Texas. John has authored or co-authored numerous peer-reviewed research papers in the areas of cardiovascular pharmacology, clinical pharmacology, and drug development.